Enliven Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
ELVN$51.20-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(42,688) | $(31,445) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 157 | 141 |
| Stock-based compensation | 9,659 | 6,457 |
| Non-cash lease expense | 159 | — |
| Amortization of premiums and discounts on marketable securities, net | (1,264) | (831) |
| Change in fair value of contingent value right liability | (800) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses, other current and long-term assets | (6,087) | (5,762) |
| Operating lease liabilities | (166) | (2) |
| Accounts payable | 551 | 304 |
| Accrued expenses and other liabilities | (3,317) | (1,755) |
| Net cash used in operating activities | (43,796) | (32,893) |
| Cash flows from investing activities: | ||
| Maturities of marketable securities | 116,079 | — |
| Purchases of marketable securities | (177,607) | (151,430) |
| Receipt of contingent value right milestone payment | 10,000 | — |
| Purchases of property and equipment | (22) | (119) |
| Net cash used in investing activities | (51,550) | (151,549) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 2,061 | 281 |
| Proceeds from issuance of common stock under the ESPP | 320 | — |
| Proceeds from issuance of common stock and Pre-Funded Warrants in the Private Placement, net of issuance costs | 89,695 | — |
| Payment of deferred offering costs related to the Sales Agreement | — | (110) |
| Proceeds from the Financing Transaction, net of issuance costs | — | 161,365 |
| Cash acquired in connection with the reverse recapitalization | — | 81,821 |
| Payment of reverse recapitalization transaction costs | — | (8,736) |
| Net cash provided by financing activities | 92,076 | 234,621 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (3,270) | 50,179 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 100,195 | 75,590 |
| Cash, cash equivalents and restricted cash at the end of the period | $96,925 | $125,769 |
| Components of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $96,871 | $125,715 |
| Restricted cash | 54 | 54 |
| Total cash, cash equivalents and restricted cash | $96,925 | $125,769 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Conversion of convertible preferred stock to common stock | $— | $149,749 |
| Deferred offering costs related to the Sales Agreement included in accounts payable and accrued expenses and other current liabilities | $— | $414 |
| Purchases of property and equipment included in accrued expenses and other current liabilities | $23 | $— |
| Receivables from stock option exercises included in prepaid expenses and other current assets | $118 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.